Skip to main content
. 2021 Oct 19;28(5):4234–4246. doi: 10.3390/curroncol28050359

Figure 2.

Figure 2

Patients with advanced-stage HGSOC with omental CD68+ or CD163+ CLSs have poorer OS and PFS than those without omental CLSs. In advanced-stage HGSOC (n = 116), patients with omental CD68+ CLSs (no. ≥ 1) (A) or omental CD163+ CLSs (no. ≥ 1) (B) had worse OS (median survival: 24 vs. 38 months; 22 vs. 36 months, respectively, p = 0.001; p = 0.002). Patients with omental CD68+ (C) or CD163+ (D) CLSs had poor PFS (median survival: 11 vs. 15 months; 11 vs. 15 months, respectively p = 0.001, 0.001).